nach oben

Erschienen in:

01.05.2014 | Original Article

Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations

verfasst von: Kathleen A. Griffith, Darren J. Couture, Shijun Zhu, Naimish Pandya, Mary E. Johantgen, Guido Cavaletti, Joan M. Davenport, Lori J. Tanguay, Amanda Choflet, Todd Milliron, Erica Glass, Nancy Gambill, Cynthia L. Renn, Susan G. Dorsey

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is increasing with introduction of new and combination cancer pharmacotherapies. This study evaluated associations between clinical and self-report measurements and current perception threshold (CPT), a neuroselective measure of sensory nerve function that may detect asymptomatic CIPN damage.

Methods

Data for this secondary analysis were from a prospective, observational study using CPT to evaluate CIPN. Bivariate mixed models, accounting for the intraclass correlation between repeated patient assessments, were used to assess the relationship between CPT at each frequency (5, 250, and 2,000 Hz) and each subjective measure (Neuropathic Pain Scale, FACT-GOGntx) and objective measurement (quantitative sensory testing, deep tendon reflexes, and grip strength).

Results

A total of 29 chemotherapy-naïve subjects with various cancer types had a mean age of 56.7 (SD 10.4); nine subjects developed CIPN grade >1 using NCI CTC-AE criteria. Cold detection thresholds were inversely associated with CPT 5 [b(95 % CI) = −2.5(−4.5, −0.5)] and CPT 2,000 [−7.5(−11.8, −3.3)] frequencies. FACT GOG-ntx quality of life (QoL) scale and neurotoxicity and function subscales were inversely associated with CPT 2,000 [−1.8 (−3.5, −0.05), −2.2 (−4.2, −0.2), and −5.4 (−9.8, −0.9), respectively], indicating worsening QoL, impairment, and function as hypoesthesia increases.

Conclusions

CPT 2,000 may identify impending worsening of patient-reported outcomes such as QoL.

Edwards BK et al (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427PubMedCrossRef

World Health Organization (2001) International Classification of Functioning, Disability, and health (ICF)

Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633–1642PubMedCrossRef

Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42(1):24–30PubMedCrossRef

Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11(5):509–513PubMedCrossRef

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17PubMedCrossRef

Chaudhry V et al (1994) Inter- and intraexaminer reliability of nerve conduction measurements in patients with diabetic neuropathy. Neurology 44(8):1459–1462PubMedCrossRef

Polomano RC et al (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94(3):293–304PubMedCrossRef

Roytta M, Raine CS (1985) Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 14(1):157–175PubMedCrossRef

10.

Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRef

11.

Fischer SJ et al (2001) Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo. Neurobiol Dis 8(6):1027–1035PubMedCrossRef

12.

Andre T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351PubMedCrossRef

13.

Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181PubMedCrossRef

14.

Oken MM et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655PubMedCrossRef

15.

Miller AB et al (1981) Reporting results of cancer treatment. Cancer 47(1):207–214PubMedCrossRef

16.

Cavaletti G et al (2006) Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135–141PubMedCrossRef

17.

Wolf S et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515PubMedCrossRef

18.

Ma L et al (2012) Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. J Pharmacol Sci 119(3):282–286PubMedCrossRef

19.

Matsumoto M et al (2006) Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol Pain 2:16PubMedCentralPubMedCrossRef

20.

Matsumoto M et al (2008) Pharmacological switch in Abeta-fiber stimulation-induced spinal transmission in mice with partial sciatic nerve injury. Mol Pain 4:25PubMedCentralPubMedCrossRef

21.

Koga K et al (2005) Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. Mol Pain 1:13PubMedCentralPubMedCrossRef

22.

Katims JJ et al (1987) Constant current sine wave transcutaneous nerve stimulation for the evaluation of peripheral neuropathy. Arch Phys Med Rehabil 68(4):210–213PubMed

23.

Takekuma K et al (2000) Age and gender differences in skin sensory threshold assessed by current perception in community dwelling Japanese. J Epidemiol 10(1):S33–S38PubMedCrossRef

24.

Rendell MS et al (1989) Mapping diabetic sensory neuropathy by current perception threshold testing. Diabetes Care 12(9):636–640PubMedCrossRef

25.

Rendell MS et al (1989) A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy. J Neurol Neurosurg Psychiatry 52(4):502–511PubMedCentralPubMedCrossRef

26.

Masson EA, Boulton AJ (1991) The Neurometer: validation and comparison with conventional tests for diabetic neuropathy. Diabet Med 8(Spec No):S63–S66PubMedCrossRef

27.

Nishimura H et al (2004) Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer. Gan To Kagaku Ryoho 31(4):627–630PubMed

28.

Tack CJ et al (1994) Comparison of clinical examination, current and vibratory perception threshold in diabetic polyneuropathy. Neth J Med 44(2):41–49PubMed

29.

Doi D et al (2003) Evaluation of the neurotoxicity of paclitaxel and carboplatin by current perception threshold in ovarian cancer patients. J Nihon Med Sch 70(2):129–134CrossRef

30.

Rolke R, Baron R, Maier C et al (2006) Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 123(3):231–243PubMedCrossRef

31.

Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCentralPubMedCrossRef

32.

Galer BS, Jensen MP (1997) Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48(2):332–338PubMedCrossRef

33.

Calhoun EA et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748PubMedCrossRef

34.

Huang HQ et al (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393PubMedCrossRef

35.

Bell-Krotoski JA et al (1995) Threshold detection and Semmes-Weinstein monofilaments. J Hand Ther 8(2):155–162PubMedCrossRef

36.

de Sonnaville JJ et al (1997) The prevalence and determinants of foot ulceration in type II diabetic patients in a primary health care setting. Diabetes Res Clin Pract 35(2–3):149–156PubMedCrossRef

37.

Felix E, Widerstrom E (2009) Reliability and validity of quantitative sensory testing in persons with spinal cord injury and neuropathic pain. J Rehabil Res Dev 46:69–84PubMedCrossRef

38.

Hilz MJ, Dutsch M, Neundorfer B (1998) Autonomic disorders in polyneuropathies. Med Klin (Munich) 93(9):533–540CrossRef

39.

Martina IS et al (1998) Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 65(5):743–747PubMedCentralPubMedCrossRef

40.

Merkies IS et al (2000) Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. The Inflammatory Neuropathy Cause and Treatment (INCAT) Group. J Neurol Neurosurg Psychiatry 68(5):669–671PubMedCentralPubMedCrossRef

41.

Smieja M et al (1999) Clinical examination for the detection of protective sensation in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med 14(7):418–424PubMedCentralPubMedCrossRef

42.

Hallett M (1993) NINDS myotatic reflex scale. Neurology 43(12):2723PubMedCrossRef

43.

Richardson JK (2002) The clinical identification of peripheral neuropathy among older persons. Arch Phys Med Rehabil 83(11):1553–1558PubMedCrossRef

44.

Fauci AS et al (ed) (2012) Harrison’s principles of internal medicine, 18ed.

Titel: Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations
verfasst von: Kathleen A. Griffith
Darren J. Couture
Shijun Zhu
Naimish Pandya
Mary E. Johantgen
Guido Cavaletti
Joan M. Davenport
Lori J. Tanguay
Amanda Choflet
Todd Milliron
Erica Glass
Nancy Gambill
Cynthia L. Renn
Susan G. Dorsey
Publikationsdatum: 01.05.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 5/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-2068-0

Springer Medizin

Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations